198 related articles for article (PubMed ID: 37325638)
1. Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.
Shi YY; Wang AJ; Liu XL; Dai MY; Cai HB
Front Immunol; 2023; 14():1193222. PubMed ID: 37325638
[TBL] [Abstract][Full Text] [Related]
2. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
Shi YY; Dong DR; Fan G; Dai MY; Liu M
Front Immunol; 2023; 14():1237964. PubMed ID: 37849747
[TBL] [Abstract][Full Text] [Related]
3. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).
Wang Y; Zhou Y; Cao S; Sun Y; Dong Z; Li C; Wang H; Yao Y; Yu H; Song X; Li M; Wang J; Wei M; Yang G; Yang C
Bioorg Chem; 2021 Jun; 111():104833. PubMed ID: 33839580
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
10. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
11. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
12. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.
Zhang SA; Niyazi HE; Hong W; Tuluwengjiang GL; Zhang L; Zhang Y; Su WP; Bao YX
Tumour Biol; 2017 Mar; 39(3):1010428317692237. PubMed ID: 28351328
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets.
Awadasseid A; Wang R; Sun S; Zhang F; Wu Y; Zhang W
Biomed Pharmacother; 2024 Mar; 172():116257. PubMed ID: 38350367
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy.
Zhang C; Xu M; He S; Huang J; Xu C; Pu K
Adv Mater; 2023 Feb; 35(6):e2208553. PubMed ID: 36427459
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer.
Wang K; Zhou H
Drug Dev Res; 2021 May; 82(3):422-429. PubMed ID: 33231319
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Yao H; Lan J; Li C; Shi H; Brosseau JP; Wang H; Lu H; Fang C; Zhang Y; Liang L; Zhou X; Wang C; Xue Y; Cui Y; Xu J
Nat Biomed Eng; 2019 Apr; 3(4):306-317. PubMed ID: 30952982
[TBL] [Abstract][Full Text] [Related]
19. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
[No Abstract] [Full Text] [Related]
20. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.
Skalniak L; Zak KM; Guzik K; Magiera K; Musielak B; Pachota M; Szelazek B; Kocik J; Grudnik P; Tomala M; Krzanik S; Pyrc K; Dömling A; Dubin G; Holak TA
Oncotarget; 2017 Sep; 8(42):72167-72181. PubMed ID: 29069777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
